Publications by Raju Mukherjee

Fluorescent Benzothiazinone Analogues Efficiently and Selectively Label Dpre1 in Mycobacteria and Actinobacteria

Paul Joseph Dyson, Stewart Cole, John McKinney, Neeraj Dhar, Thierry Laroche, Jérémie Piton, Joao Pedro De Almeida Neres, Raphael Christopher Sommer, Raju Mukherjee

Benzothiazinones (BTZ) are highly potent bactericidal inhibitors of mycobacteria and the lead compound, BTZ043, and the optimized drug candidate, PBTZ169, have potential for the treatment of tuberculosis. Here, we exploited the tractability of the BTZ scaf ...

2018

GtrA Protein Rv3789 Is Required for Arabinosylation of Arabinogalactan in Mycobacterium tuberculosis

Stewart Cole, Matteo Dal Peraro, Claudia Sala, Luciano Andres Abriata, Raju Mukherjee, Gaëlle Séraphine Kolly, Mahé Cécile Raccaud

Mycobacterium tuberculosis possesses a thick and highly hydrophobic cell wall principally composed of a mycolyl-arabinogalactan-peptidoglycan complex, which is critical for survival and virulence. DprE1 is a well-characterized component of decaprenyl-phosp ...

American Society for Microbiology2015

DprE1 Is a Vulnerable Tuberculosis Drug Target Due to Its Cell Wall Localization

Stewart Cole, Gaëlle Séraphine Kolly, Joao Pedro De Almeida Neres, Raju Mukherjee

The flavo-enzyme DprE1 catalyzes a key epimerization step in the decaprenyl-phosphoryl d-arabinose (DPA) pathway, which is essential for mycobacterial cell wall biogenesis and targeted by several new tuberculosis drug candidates. Here, using differential r ...

American Chemical Society2015

Structural studies suggest a peptidoglycan hydrolase function for the Mycobacterium tuberculosis Tat-secreted protein Rv2525c

Stewart Cole, Raju Mukherjee, Sophie Magnet

Among the few proteins shown to be secreted by the Tat system in Mycobacterium tuberculosis, Rv2525c is of particular interest, since its gene is conserved in the minimal genome of Mycobacterium leprae. Previous evidence linked this protein to cell wall me ...

Elsevier2014

Towards a new tuberculosis drug: pyridomycin - nature's isoniazid

Stewart Cole, Florence Pojer, Claudia Sala, Ruben Hartkoorn, Joao Pedro De Almeida Neres, Swapna Uplekar, Raju Mukherjee, Sophie Magnet

Tuberculosis, a global threat to public health, is becoming untreatable due to widespread drug resistance to frontline drugs such as the InhA-inhibitor isoniazid. Historically, by inhibiting highly vulnerable targets, natural products have been an importan ...

Wiley Open Access2012